Car rental stocks surged today after Hertz Global (HTZ) reported a significant increase in website traffic as travelers look for alternatives to flying amid a TSA shortage that has led to unusually long airport security lines across the United States.The ongoing federal funding lapse for the U.S. Department of Homeland Security (DHS) has led to TSA officers going without pay, driving many to quit or to call out sick. Hertz shares spiked 9% on Thursday, pulling Avis Budget Group's (CAR) stock up in the proce ...

A well-timed marketing campaign and chaos at U.S. airports are among the factors making Avis Budget Group (CAR +12.96%) shares very attractive to investors these days. On Thursday, the auto rental conglomerate's stock surged 13% on a generally gloomy day for the market.Time to hit the roadThe current political impasse over the continued funding of the Department of Homeland Security (DHS) has directly affected the functioning of airports. The Transportation Security Administration (TSA) is a sub-agency of t ...

Lyell Immunopharma, Inc. ( LYEL ) is a CAR-T therapy developer. The story is centered around a single asset known as ronde-cel. Target indication is LBCL, where it demonstrated 93% ORR, 76% CR, and ~18-month mPFS inMr Arunangshu Das is a software engineer, a finance and billing architect, and an active investor and entrepreneur. He is developing Tranzoro Investments to fill a critical lacunae - to help US investors understand Indian markets, and Indian investor understand US markets. For the former, he will ...

A month has gone by since the last earnings report for Avis Budget Group (CAR) . Shares have added about 3.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Avis Budget due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Avis Budget Group, Inc. before we dive into how investors and analysts have reacted as of late.Avis Budget ...

Core Insights - Avis Budget Group reported an adjusted EBITDA growth of 11% for Q4 2025, but under GAAP, the company posted a significant net loss of $856 million [1] - The previous CEO projected that Avis would generate no less than $1 billion of adjusted EBITDA in 2025, but the actual full-year adjusted EBITDA was only $748 million, missing the forecast by approximately $150 million [2] Financial Performance - Adjusted EBITDA for Q4 2025 increased by 11% [1] - GAAP results indicated a net loss of $856 million [1] - Full-year adjusted EBITDA was reported at $748 million, falling short of the $1 billion target [2] Leadership Changes - The company transitioned from then-CEO Joseph Ferraro to new CEO Brian Choi, who reaffirmed the $1 billion adjusted EBITDA target during the Q3 2025 earnings call [2]

Group 1 - The allogeneic CAR-T sector faced significant setbacks after the FDA imposed a clinical hold on Allogene's ALLO-501A in 2021, leading to a drastic drop in stock price from $25/share to $13/share in a single day [1] - The biotech sector is perceived to be on the verge of a transformative era, with expectations for revolutionary breakthroughs in treating diseases such as cancer, Alzheimer's, and various autoimmune disorders [1] - Technological advancements are anticipated to accelerate, with innovations like fusion energy, solid-state batteries, and nanomaterials expected to become prevalent in the near future [1] Group 2 - The author has a beneficial long position in the shares of CRBU, indicating a personal investment interest in the company [2] - The article reflects the author's personal opinions and is not influenced by any compensation from companies mentioned [2]

Group 1 - Avis Budget Group reported an adjusted EBITDA growth of 11% for Q4 2025, but under GAAP, the company posted a net loss of $856 million [1] - The previous CEO Joseph Ferraro projected that Avis would generate no less than $1 billion of adjusted EBITDA in 2025, a target reaffirmed by the new CEO Brian Choi [2] - Avis reported a full year adjusted EBITDA of $748 million, missing the fourth quarter forecast by approximately $150 million [2] Group 2 - The company is facing legal inquiries as shareholders who lost money are encouraged to submit their information for potential claims [1][2]

Core Viewpoint - Avis Budget Group reported a significant Q4 2025 GAAP net loss of $856 million, with revenue falling short of analyst expectations by approximately $80 million, leading to substantial shareholder losses [1] Financial Performance - The Q4 2025 loss was primarily attributed to a material write-down of the company's electric vehicle fleet, which directly impacted the value of vehicles used as collateral for $965 million in asset-backed securities [1] - The adjusted loss for Q4 2025 was reported at $747 million, indicating a sharp decline in the company's financial condition compared to earlier statements made by the then-CFO, who had assured investors of no further fleet-related charges [1] Shareholder Impact - Shareholders who invested in Avis Budget Group and experienced losses are encouraged to submit their information for potential legal recourse [1]

Core Insights - Citius Oncology announced positive topline results from a Phase 1 trial of LYMPHIR (E7777) showing an 86% overall response rate in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1] - The trial demonstrated effective Treg depletion and promising efficacy signals, with no dose-limiting toxicities observed [1][2] - LYMPHIR is FDA-approved for treating relapsed or refractory cutaneous T-cell lymphoma and is being investigated for its potential to enhance CAR-T therapy efficacy [1][2] Company Overview - Citius Oncology, Inc. is focused on developing and commercializing novel targeted oncology therapies, with LYMPHIR launched in December 2025 for treating adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Study Design and Results - The Phase 1 trial was an open-label, dose-escalation study involving 14 patients with poor prognostic features, who received LYMPHIR followed by standard commercial CD19-directed CAR-T therapy [1] - Key findings included a median reduction of 24 Tregs/µL and a favorable safety profile, with all patients completing treatment and proceeding to CAR-T infusion [1][2] - The study's design aimed to augment lymphodepletion prior to CAR-T infusion, potentially improving antitumor activity [1] Treatment Context - DLBCL accounts for approximately 30%-40% of newly diagnosed non-Hodgkin lymphoma cases in the U.S., with high-risk features associated with poor outcomes [1] - Novel strategies like transient regulatory T-cell depletion are being explored to improve treatment efficacy in this challenging patient population [1]

Core Viewpoint - Kaskela Law LLC is investigating the proposed buyout of Mister Car Wash, Inc. to assess the fairness of the $7.00 per share offer for investors [1][3]. Group 1: Buyout Details - On February 18, 2026, Mister Car Wash announced an agreement to be acquired by Leonard Green & Partners L.P. at a price of $7.00 per share in cash, after which the company's shares will cease to be publicly traded [2]. - The buyout price of $7.00 per share is notably lower than the price targets set by several stock analysts, which were over $8.00 per share, indicating a potential undervaluation of the company [3]. Group 2: Investigation Purpose - The investigation aims to determine if the financial consideration offered to Mister Car Wash investors is sufficient or if the buyout price is inadequately low [3]. - Investors are encouraged to learn more about their legal rights and options regarding the investigation [4].